Kura Oncology’s Promising Prospects: Buy Rating Affirmed on Strong KOMET-001 Data and FDA Priority Review

In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target of $28.00.

Roger Song has given his Buy rating due to a combination of factors that highlight Kura Oncology’s promising prospects. The recent pivotal data from the KOMET-001 study in relapsed/refractory NPM1-mutated AML showcased impressive efficacy and safety results, including a complete response rate of 23% and a median overall survival of 16.4 months in responders. These results, along with the FDA’s acceptance of the New Drug Application with Priority Review, reinforce confidence in the potential approval of ziftomenib, Kura’s lead candidate, by the end of 2025.
Furthermore, the data revealed consistent efficacy across various subgroups, suggesting broad applicability and competitive advantages over existing standards of care. The favorable safety profile, with low discontinuation rates and manageable side effects, adds to the drug’s appeal. The company’s strategic focus on first-line settings and the upcoming updates from the KOMET-007 study are expected to further emphasize ziftomenib’s advantages, supporting the Buy rating as Kura Oncology progresses towards pivotal trials and potential commercialization.

Song covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, United Therapeutics, and TG Therapeutics. According to TipRanks, Song has an average return of -20.6% and a 28.14% success rate on recommended stocks.

In another report released today, Citizens JMP also reiterated a Buy rating on the stock with a $28.00 price target.